We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.51%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$201M
AUM Growth
-$42.4M
Cap. Flow
+$13M
Cap. Flow %
6.49%
Top 10 Hldgs %
47.8%
Holding
87
New
12
Increased
27
Reduced
14
Closed
4

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$4.12M
2
VKTX icon
Viking Therapeutics
VKTX
+$2.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$1.82M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.8M
5
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$1.46M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.9M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.46M
3
NVAX icon
Novavax
NVAX
+$1.32M
4
KURA icon
Kura Oncology
KURA
+$1.22M
5
IMDZ
Immune Design Corp.
IMDZ
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 88.58%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAT
26
DELISTED
BioTelemetry, Inc.
BEAT
$2.56M 1.27%
42,800
-4,000
-9% -$240K
YARW
27
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$2.23M 1.11%
150
+63
+72% +$1.41M
KURA icon
28
Kura Oncology
KURA
$800M
$2.09M 1.04%
148,617
-91,883
-38% -$1.22M
WVE icon
29
Wave Life Sciences
WVE
$1.09B
$2.01M 1%
47,900
– –
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.89M 0.94%
66,200
+10,000
+18% +$318K
TVRD
31
Tvardi Therapeutics
TVRD
$19.7M
$1.87M 0.93%
3,989
+855
+27% +$552K
TBIO
32
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$1.72M 0.85%
228,939
+77,200
+51% +$566K
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.06B
$1.5M 0.75%
237,683
– –
VKTX icon
34
Viking Therapeutics
VKTX
$3.7B
$1.37M 0.68%
+179,200
New +$2.14M
INCY icon
35
Incyte
INCY
$24.2B
$1.37M 0.68%
21,500
– –
VBIV
36
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$1.36M 0.68%
28,333
-2,823
-9% -$155K
CNCE
37
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.33M 0.66%
+105,656
New +$1.46M
NTUS
38
DELISTED
Natus Medical Inc
NTUS
$1.29M 0.64%
37,900
– –
ARQL
39
DELISTED
Arqule Inc
ARQL
$1.27M 0.63%
457,664
+10,000
+2% +$38.2K
DRNA
40
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.27M 0.63%
118,500
– –
NVRO
41
DELISTED
NEVRO CORP.
NVRO
$1.21M 0.6%
+31,210
New +$1.39M
JNJ icon
42
Johnson & Johnson
JNJ
$618B
$1.21M 0.6%
9,400
– –
CYTK icon
43
Cytokinetics
CYTK
$10.5B
$1.17M 0.58%
185,826
+123,136
+196% +$903K
IMMU
44
DELISTED
Immunomedics Inc
IMMU
$1.17M 0.58%
82,254
-95,746
-54% -$1.9M
ASMB icon
45
Assembly Biosciences
ASMB
$498M
$1.14M 0.57%
4,214
+3,325
+374% +$962K
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
$1M 0.5%
630,182
-217,454
-26% -$615K
MGNX icon
47
MacroGenics
MGNX
$235M
$994K 0.49%
78,305
– –
ABUS icon
48
Arbutus Biopharma
ABUS
$857M
$946K 0.47%
+246,900
New +$1.22M
CRBP icon
49
Corbus Pharmaceuticals
CRBP
$166M
$905K 0.45%
+5,167
New +$1.03M
AGTC
50
DELISTED
Applied Genetic Technologies Corporation
AGTC
$894K 0.44%
359,190
-670
-0.2% -$3.92K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, DAFNA Capital Management held 87 positions worth $201M, down 17% from $244M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $13M of net new capital in Q4 2018, opening 12 new positions and adding to 27 existing holdings. Its largest new stake was Viking Therapeutics: 179,200 shares worth $1.37M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.9M trimmed.

  • DAFNA Capital Management's largest Q4 2018 buy was Viking Therapeutics: 179,200 shares worth $1.37M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q4 2018, an estimated $4.12M increase.
  • DAFNA Capital Management's biggest Q4 2018 reduction was Immunomedics Inc, cutting an estimated $1.9M.
  • DAFNA Capital Management fully exited Novavax in Q4 2018, selling an estimated $1.32M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $201M portfolio in Q4 2018.
  • DAFNA Capital Management opened 12 new positions and closed 4 in Q4 2018.
  • DAFNA Capital Management's portfolio value fell 17% quarter-over-quarter to $201M.

Based on DAFNA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.